摘要
目的:研究利伐沙班和低分子量肝素(Low Molecular Weight Heparin,LMWH)对肿瘤患者凝血功能影响,以及两种药物的安全性和有效性。方法:选取2019年7月至2022年7月我院收治确诊恶性肿瘤并接受化疗的患者60例,其中使用利伐沙班预防静脉血栓30例为试验组,使用LMWH预防静脉血栓30例为对照组。对比用药前后两组患者凝血功能,用药后血栓及大出血事件发生情况。结果:两组患者肿瘤位、基础疾病未见明显差异;两组患者血栓预防治疗后较治疗前D-二聚体数值均明显下降(P<0.05);两组患者均未见血栓及大出血事件发生。结论:利伐沙班和LMWH在接受化疗的肿瘤患者血栓预防中,安全性和有效性均有明确效果,均可明显降低患者D-二聚体,可使用利伐沙班代替LMWH预防肿瘤静脉血栓。
Objective:To study the effects of rivaroxaban and low molecular weight heparin(LMWH)on the coagulation function of tumor patients,as well as the safety and efficacy.Methods:A total of 60 patients with malignant tumors diagnosed and treated with chemotherapy were selected in our hospital from July 2019 to July 2022.Thirty patients treated with rivaroxaban were selected as the test group,and thirty patients treated with LMWH were selected as the control group.The coagulation indexes before and after medication,thrombosis and major bleeding events were compared between the two groups.Results:There were no significant differences in tumor location,underlying disease between the two groups;The D-dimer between the two groups after thrombus prophylaxis and before treatment were decreased significantly(P<0.05).No thrombus or major bleeding occurred in the two groups.Conclusion:Both rivaroxaban and LMWH have a clear effect on safety and efficacy in the prevention of thrombosis in tumor patients receiving chemotherapy,and both can significantly reduce patients'D-Dimer.Rivaroxaban might be used to prevent tumor-associated venous thromboembolism instead of LMWH.decreased D-dimer more significantly than LMWH.
作者
李博
周琴
陈丽霞
LI Bo;Zhou Qin;Chen Li-Xia(Department of Pharmacy,Shangrao People's Hospital,Shangrao 334000,Jiangxi,China;Department of Pediatrics,Shangrao People's Hospital,Shangrao 334000,Jiangxi,China)
基金
江西省卫生健康委科技计划(编号:202140923)。
关键词
利伐沙班
低分子量肝素
恶性肿瘤
静脉血栓
凝血功能
Rivaroxaban
Low molecular weight heparin
Malignant tumor
Venous thrombosis
Coagulation function
作者简介
李博,男,主管药师,主要从事于抗凝药物治疗工作,Email:17879310766@163.com;通讯作者:陈丽霞,女,主任医师,主要从事于儿科工作,Email:1623379318@qq.com。
